SG Americas Securities LLC Raises Stock Position in Zoetis Inc. $ZTS

SG Americas Securities LLC boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 400.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 276,529 shares of the company’s stock after purchasing an additional 221,294 shares during the period. SG Americas Securities LLC’s holdings in Zoetis were worth $34,793,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ZTS. North Star Asset Management Inc. raised its position in shares of Zoetis by 4.9% during the 2nd quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock worth $225,000 after purchasing an additional 67 shares during the last quarter. Bank of Nova Scotia Trust Co. boosted its holdings in Zoetis by 4.6% in the 2nd quarter. Bank of Nova Scotia Trust Co. now owns 1,692 shares of the company’s stock worth $264,000 after buying an additional 74 shares during the last quarter. Summit Place Financial Advisors LLC increased its stake in Zoetis by 0.4% during the 3rd quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company’s stock worth $2,834,000 after buying an additional 76 shares in the last quarter. First County Bank CT increased its stake in Zoetis by 5.4% during the 3rd quarter. First County Bank CT now owns 1,535 shares of the company’s stock worth $225,000 after buying an additional 79 shares in the last quarter. Finally, CWA Asset Management Group LLC raised its holdings in shares of Zoetis by 1.1% during the third quarter. CWA Asset Management Group LLC now owns 7,236 shares of the company’s stock valued at $1,059,000 after acquiring an additional 80 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Up 0.6%

Shares of Zoetis stock opened at $116.65 on Thursday. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The stock’s 50 day simple moving average is $123.79 and its 200-day simple moving average is $129.67. The stock has a market cap of $49.24 billion, a P/E ratio of 19.38, a P/E/G ratio of 1.77 and a beta of 0.95. Zoetis Inc. has a 1-year low of $113.30 and a 1-year high of $172.23.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. During the same quarter last year, the firm earned $1.40 earnings per share. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s payout ratio is currently 35.22%.

Analysts Set New Price Targets

Several research firms have recently weighed in on ZTS. Bank of America raised their target price on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Piper Sandler restated a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. BTIG Research reaffirmed a “buy” rating and set a $160.00 target price on shares of Zoetis in a research note on Thursday, February 26th. Finally, UBS Group set a $136.00 target price on shares of Zoetis in a report on Thursday, January 29th. Six investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.